Unknown PHASE2 INTERVENTIONAL 1-arm NCT04235179

Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer (ASPIRE)

Sponsor: King Saud University

Interventions SABR

Updated 5 times since 2020 Last updated: Jan 19, 2020 Started: Jan 16, 2020 Primary completion: Jan 31, 2022 Completion: Jan 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Endometrial Cancer, this trial is ongoing. The trial is conducted by King Saud University and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

King Saud University

Data source: King Saud University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Riyadh, Saudi Arabia